Precision for Medicine Names Amanda Owens GM of Biospecimen Solutions to Expand Access to Characterized Samples
核心洞察
Precision for Medicine (搜索) has appointed Amanda Owens as General Manager of Biospecimen Solutions to lead the business's commercial and operational strategy.
The appointment responds to growing biopharma demand for deeply annotated, molecularly characterized biospecimens supporting increasingly complex drug development.
Precision for Medicine (搜索) maintains biorepositories holding more than one million biofluid specimens and three million tissue specimens paired with laboratory characterization capabilities.
Precision for Medicine (搜索), a global leader in biomarker-driven clinical research and development, has appointed Amanda Owens as General Manager of Biospecimen Solutions, the company announced on Aug. 20, 2026. Owens will lead the business's commercial and operational strategy, with a mandate to expand access to fit-for-purpose, deeply annotated biospecimens that support the research and development of next-generation therapies.
The appointment comes as biopharma research increasingly demands biospecimens that are rich in genetic and molecular data. "As biopharma shifts toward increasingly complex modalities, access to fully characterized biological samples has become a strategic imperative," said Sofia Baig, President of Precision for Medicine (搜索).
A Strategic Response to Evolving Research Needs
Precision for Medicine (搜索) maintains biorepositories that include over one million biofluid specimens and three million tissue specimens. Baig emphasized that pairing this vast repository with deep molecular characterization "gives our clients the clarity and confidence needed to accelerate drug discovery," adding that Owens' expertise "will help ensure the market taps into this depth and that we deliver the quality and speed our clients require."
The company's strategy positions its biospecimen operation as part of a broader research infrastructure rather than solely a sourcing service. By combining specimen inventory with molecular characterization and laboratory capabilities, Precision for Medicine (搜索) aims to support researchers as scientific requirements change throughout a development program.
From Transactional Sourcing to Consultative Partnership
Owens framed the industry's central challenge in matching specimens to projects. "Matching the right biospecimen to the right project at the right time is one of the central challenges in our industry. This means we need to understand what a sponsor requires today, and what's needed as their research evolves," she said.
She also underscored the importance of quality and biological characterization. "Precision for Medicine (搜索) realizes this at a deeper level because our laboratory capabilities allow us to go beyond simply providing a biospecimen to understand and characterize the biology behind it. That combination creates an opportunity to move beyond transactional sourcing toward true consultative partnerships."
Leadership Background
Owens brings extensive life sciences experience spanning biospecimen services, genomics, gene editing and advanced therapies, with a track record of building commercial organizations, directing operational execution and expanding strategic partnerships. A veteran of the biospecimen industry, she has held senior commercial leadership roles at Landmark Bio (搜索) and Discovery Life Sciences (搜索).
She holds an MBA from the University of Alabama in Huntsville, a master's degree in Biological Anthropology and a bachelor's degree in Biology from the University of Alabama. She is based in Nashville, Tennessee.
A Broader Convergence in Clinical Research
The appointment reflects a wider convergence within the clinical research services market, where biospecimen sourcing, laboratory analysis, biomarker strategy, clinical trial execution and data intelligence are becoming increasingly interconnected. As drug developers seek to identify which patients are most likely to benefit from increasingly targeted treatments, access to appropriately characterized biological material has become a more strategic part of the research process.
Precision for Medicine (搜索) is part of Precision Medicine Group (搜索), which employs more than 3,500 people across more than 50 locations in the Americas, Europe and Asia-Pacific.